By Fineline Cube Yipinhong Pharmacy Co., Ltd. (SHE: 300723) announced it has received Investigational New Drug (IND) clearance from China’s National Medical Products Administration (NMPA) to initiate a clinical study evaluating APH03571, a novel dual-mechanism therapeutic agent, in adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring FLT3 mutations.
Regulatory & Development Milestone
| Item | Detail |
|---|---|
| Company | Yipinhong Pharmacy Co., Ltd. (SHE: 300723) |
| Drug Candidate | APH03571 |
| Drug Class | Dual-mechanism agent (FLT3 inhibitor + IRAK4 degrader) |
| Regulatory Authority | National Medical Products Administration (NMPA), China |
| Approval Type | IND clearance for clinical investigation |
| Target Population | Adult patients with relapsed/refractory AML harboring FLT3 mutations |
| Development Stage | Clinical trial initiation |
| Announcement Date | 11 Jun 2026 |
Drug Profile & Mechanism of Action
- Dual Mechanism: Simultaneous FLT3 kinase inhibition and IRAK4 protein degradation
- Primary Target: FLT3 (FMS-like tyrosine kinase 3) – frequently mutated in AML and associated with poor prognosis
- Secondary Target: IRAK4 (Interleukin-1 receptor-associated kinase 4) – key mediator of inflammatory signaling in leukemic cells
- Therapeutic Rationale: Addresses both oncogenic driver mutations (FLT3) and inflammatory survival pathways (IRAK4) that contribute to treatment resistance
- Preclinical Evidence: Dose-dependent tumor growth inhibition and prolonged survival in mouse xenograft models of FLT3-mutated AML
FLT3 mutations occur in approximately 30% of AML cases and are associated with high relapse rates and poor overall survival. Current FLT3 inhibitors often face limitations due to acquired resistance and compensatory signaling through alternative pathways. APH03571’s dual-targeting approach aims to overcome these challenges by simultaneously blocking the primary oncogenic driver while disrupting inflammatory survival signals mediated by IRAK4.
Market Opportunity & Competitive Landscape
- AML Patient Population: Estimated 8,000-10,000 new FLT3-mutated AML cases annually in China
- Relapsed/Refractory Segment: Represents approximately 40-50% of FLT3-mutated AML patients with limited treatment options
- Competitive Differentiation: First-in-class dual FLT3 inhibitor/IRAK4 degrader mechanism; addresses key unmet need in treatment-resistant AML
- Current Therapies: Competes against established FLT3 inhibitors (midostaurin, gilteritinib, quizartinib) but offers potential advantages in overcoming resistance
- Pricing Potential: Expected premium pricing reflecting innovative mechanism and addressable unmet need; estimated RMB 150,000-200,000 per treatment course
- Development Timeline: Phase I/II trial expected to complete by Q2 2028, with potential accelerated approval pathway given high unmet medical need
The IND clearance positions Yipinhong as an emerging player in targeted oncology therapeutics and validates the company’s dual-mechanism drug discovery platform for addressing complex resistance mechanisms in hematological malignancies.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market opportunities. Actual outcomes may differ due to clinical trial results, regulatory decisions, and competitive developments inherent in oncology drug development.-Fineline Info & Tech